{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:23:51Z","timestamp":1791062631813,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010400","name":"Children's Mercy Hospital","doi-asserted-by":"publisher","award":["00000023728"],"award-info":[{"award-number":["00000023728"]}],"id":[{"id":"10.13039\/100010400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001099","name":"Ernst & Young Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.ajpath.2012.07.017","type":"journal-article","created":{"date-parts":[[2012,8,31]],"date-time":"2012-08-31T02:25:58Z","timestamp":1346379958000},"page":"1672-1680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Combined Inhibition of c-Abl and PDGF Receptors for Prevention and Treatment of Murine Sclerodermatous Chronic Graft-versus-Host Disease"],"prefix":"10.1016","volume":"181","author":[{"given":"Pawel","family":"Zerr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfiya","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Palumbo-Zerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Tomcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Vollath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Dees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Tinazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd M.","family":"Spriewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg H.W.","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2012.07.017_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00281-004-0165-3","article-title":"Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review","volume":"26","author":"Baron","year":"2004","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.ajpath.2012.07.017_bib2","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2012.07.017_bib3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.moh.0000245689.47333.ff","article-title":"Chronic graft versus host disease","volume":"13","author":"Baird","year":"2006","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.ajpath.2012.07.017_bib4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.TP.0000041783.34083.11","article-title":"Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease","volume":"75","author":"Clark","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.ajpath.2012.07.017_bib5","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2003-06-2073","article-title":"Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells","volume":"103","author":"Clark","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2012.07.017_bib6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.bmt.1703705","article-title":"Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis","volume":"30","author":"French","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ajpath.2012.07.017_bib7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.bmt.1705107","article-title":"IL-4-producing CD8(+) T cells may be an immunological hallmark of chronic GVHD","volume":"36","author":"Nakamura","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ajpath.2012.07.017_bib8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.tp.0000245080.71722.87","article-title":"Predominant infiltration of monocytes in chronic graft-versus-host disease","volume":"83","author":"Namba","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.ajpath.2012.07.017_bib9","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood.V58.4.746.746","article-title":"Lymphocyte dysfunction in chronic graft-versus-host disease","volume":"58","author":"Saxon","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2012.07.017_bib10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2007-01-071043","article-title":"Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease","volume":"110","author":"Svegliati","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2012.07.017_bib11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2257.2005.00699.x","article-title":"Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation","volume":"27","author":"Wechalekar","year":"2005","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.ajpath.2012.07.017_bib12","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2003-09-3286","article-title":"Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells","volume":"103","author":"Yamashita","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2012.07.017_bib13","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.bbmt.2006.08.043","article-title":"Cutaneous manifestations of chronic graft-versus-host disease","volume":"12","author":"Hymes","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ajpath.2012.07.017_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbmt.2005.10.023","article-title":"Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, I: Pathology Working Group Report","volume":"12","author":"Shulman","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ajpath.2012.07.017_bib15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0002-9343(69)90044-8","article-title":"Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls","volume":"46","author":"D'Angelo","year":"1969","journal-title":"Am J Med"},{"key":"10.1016\/j.ajpath.2012.07.017_bib16","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0889-857X(05)70296-9","article-title":"Immunopathogenesis of systemic sclerosis","volume":"22","author":"White","year":"1996","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.ajpath.2012.07.017_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.22314","article-title":"Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis","volume":"56","author":"Distler","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajpath.2012.07.017_bib18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood-2009-02-204750","article-title":"Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease","volume":"114","author":"Magro","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2012.07.017_bib19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2012.07.017_bib20","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1182\/blood-2011-03-341693","article-title":"A phase 1 study of imatinib for corticosteroid-dependent\/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies","volume":"118","author":"Chen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2012.07.017_bib21","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.24395","article-title":"The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis","volume":"60","author":"Akhmetshina","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajpath.2012.07.017_bib22","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1182\/blood-2006-08-043612","article-title":"Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host disease","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2012.07.017_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0008-8749(83)90001-1","article-title":"Chronic graft-versus-host disease (GVHD) as a model for scleroderma, I: Description of model systems","volume":"77","author":"Jaffee","year":"1983","journal-title":"Cell Immunol"},{"key":"10.1016\/j.ajpath.2012.07.017_bib24","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2004-01-0328","article-title":"Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease","volume":"104","author":"Anderson","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2012.07.017_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/art.24186","article-title":"Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis","volume":"60","author":"Akhmetshina","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajpath.2012.07.017_bib26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0003-9861(61)90291-0","article-title":"The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid","volume":"93","author":"Woessner","year":"1961","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.ajpath.2012.07.017_bib27","doi-asserted-by":"crossref","first-page":"32023","DOI":"10.1016\/S0021-9258(18)31591-6","article-title":"Platelet-derived growth factor receptor signals","volume":"269","author":"Claesson-Welsh","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2012.07.017_bib28","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1038\/sj.onc.1205017","article-title":"Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase","volume":"20","author":"Dorey","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.ajpath.2012.07.017_bib29","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1101\/gad.13.18.2400","article-title":"c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF","volume":"13","author":"Plattner","year":"1999","journal-title":"Genes Dev"},{"issue":"Suppl 1","key":"10.1016\/j.ajpath.2012.07.017_bib30","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2011.01.016","article-title":"Nilotinib: a novel, selective tyrosine kinase inhibitor","volume":"38","author":"Blay","year":"2011","journal-title":"Semin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ajpath.2012.07.017_bib31","doi-asserted-by":"crossref","first-page":"i48","DOI":"10.1136\/ard.2009.120196","article-title":"Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies","volume":"69","author":"Distler","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajpath.2012.07.017_bib32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2005.01.020","article-title":"AMN107: tightening the grip of imatinib","volume":"7","author":"O'Hare","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2012.07.017_bib33","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review","volume":"34","author":"An","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.ajpath.2012.07.017_bib34","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.seminhematol.2010.06.002","article-title":"Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one","volume":"47","author":"Jabbour","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ajpath.2012.07.017_bib35","first-page":"4564","article-title":"Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant [published correction appears in Cancer 2011, 117:230]","volume":"116","author":"Koren-Michowitz","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ajpath.2012.07.017_bib36","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2006-11-056069","article-title":"Hematopoietic lineage cell specific protein 1 (HS1) is a functionally important signaling molecule in platelet activation","volume":"110","author":"Kahner","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2012.07.017_bib37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1476-4598-6-67","article-title":"Nilotinib treatment in mouse models of P190 Bcr\/Abl lymphoblastic leukemia","volume":"6","author":"Kaur","year":"2007","journal-title":"Mol Cancer"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944012005822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944012005822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:02:17Z","timestamp":1762081337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944012005822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0002944012005822"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2012.07.017","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined Inhibition of c-Abl and PDGF Receptors for Prevention and Treatment of Murine Sclerodermatous Chronic Graft-versus-Host Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2012.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}